https://www.selleckchem.com/pr....oducts/elacridar-gf1
This provides a promising prospect for the study of GKAs as candidates for the treatment of type 2 diabetes. This review summarizes the clinical advances in GKAs.Diabetes is an independent risk factor for cardiovascular events, and cardiovascular diseases (CVD) increase the risk of death when combined with diabetes. Diabetes and coronary heart disease are like two sides of a coin, which increase each other's long-term cardiovascular events. Therefore, a glucose-lowering regimen that can change the cardiovascular outcome has b
Mi piace
Commento
Condividi
